AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.10
+0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 87.4M | 380.8M | 22.2M |
| Cost of Revenue | 20.1M | 525.0K | 42.2M | 25.4M | 3.0M |
| Gross Profit | (20.1M) | (525.0K) | 45.2M | 355.3M | 19.2M |
| Operating Expenses | |||||
| R&D Expense | 92.3M | 90.4M | 104.1M | 128.2M | 93.5M |
| SG&A Expense | 69.7M | 62.9M | 114.3M | 188.4M | 127.1M |
| General & Admin Expense | 21.9M | — | 111.6M | 178.9M | 122.7M |
| Selling & Marketing Expense | — | — | 2.7M | 9.5M | 4.4M |
| Other Expenses | (19.9M) | — | 141.5M | — | — |
| Total Operating Expenses | 142.1M | 152.8M | 359.9M | 316.5M | 220.6M |
| Cost and Expenses | 162.1M | 153.3M | 402.1M | 342.0M | 223.6M |
| Operating Income (EBIT) | (162.1M) | (153.3M) | (314.7M) | 38.8M | (201.3M) |
| Non-Operating | |||||
| Interest Income | 10.0M | 9.3M | 13.8M | 16.2M | 4.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 10.0M | 9.3M | 13.8M | 16.2M | 4.3M |
| Other Non-Op Income/Expense | 10.1M | 8.6M | 12.6M | 15.5M | 3.7M |
| Non-Operating Income (excl Interest) | (12.0M) | (8.6M) | (22.9M) | (15.5M) | (3.7M) |
| EBT (Pre-Tax Income) | (152.0M) | (144.7M) | (302.1M) | 54.3M | (197.6M) |
| Income Tax Expense | 46.0K | 46.0K | (393.0K) | 5.0M | 774.0K |
| Bottom Line | |||||
| Net Income | (152.1M) | (144.7M) | (301.7M) | 49.3M | (198.4M) |
| Earnings from Cont. Ops | (152.1M) | (144.7M) | (301.7M) | 49.3M | (198.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (152.1M) | (144.7M) | (301.7M) | 49.3M | (198.4M) |
| Per Share | |||||
| Basic EPS | ($1.41) | ($1.53) | ($4.43) | $0.73 | ($2.98) |
| Diluted EPS | ($1.41) | ($1.53) | ($4.43) | $0.70 | ($2.98) |
| Revenue Per Share | $0.00 | $0.00 | $1.28 | $5.66 | $0.33 |
| Shares | |||||
| Basic Shares Outstanding | 111.2M | 94.6M | 68.1M | 67.2M | 66.5M |
| Diluted Shares Outstanding | 111.2M | 94.6M | 68.1M | 70.0M | 66.5M |
| Profitability Metrics | |||||
| EBITDA | (149.8M) | (144.2M) | (291.0M) | 55.4M | (197.1M) |
| D&A | 369.0K | 525.0K | 904.0K | 1.1M | 487.0K |
| EBIT | (150.2M) | (144.7M) | (291.9M) | 54.3M | (197.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026